Danish manufacturing firm breaks ground in Peachtree City; 200 new jobs expected

By The Citizen -August 22, 2023

Meditec groundbreaking in Georgia

SP Meditec recently broke ground on a 120,000 square foot, state-of-the-art manufacturing facility that is expected to create 200 new jobs in Peachtree City.

The plant, which will be located off Georgia State Route 74, is scheduled to begin operations in August 2024.

Several factors played into SP Meditec’s selection of Peachtree City for their company’s US expansion. Peter Fejfer, Managing Director for the Denmark-based business, cited the south metro Atlanta community’s proximity to the world’s busiest airport, skilled workforce, and strategic location as reasons behind the decision.

“We aim to tap into Peachtree City’s talented pool of professionals and contribute to the local economy,” Fejfer stated.

SP Meditec develops, manufactures, and assembles plastic solutions for the healthcare industry. Their Peachtree City expansion marks a significant milestone in the company’s strategy and commitment to meeting the growing demand for high-quality injection molded parts worldwide.

“I’m excited to welcome SP Meditec to Peachtree City,” Mayor Kim Learnard said. “This major investment in our city not only underscores our dedication to fostering smart growth and innovation, but also solidifies Peachtree City’s position as a hub for cutting-edge advancements in the healthcare sector.”

Dividend Realty is acting as project developer for the new plant. Their subsidiary, Dividend ECS, will design the facility. Davis Construction will serve as the facility’s construction manager.

“We look forward to completing the project and are committed to continuing our growth in this new market,” Fejfer continued.

September 11, 2025
Members are invited to join G2G’s Monthly GBG Reporting Service Webinar on September 18, 2025 . The first portion ( 12:00–12:30 PM ET ) is free and open to all, offering a high-level overview of current federal funding trends. The second half ( 12:30–1:00 PM ET ) is a premium consultation available only to Georgia Life Sciences members, offering direct access to G2G’s expert team—who have helped secure over $550 million in non-dilutive government funding since 2007. Register here: https://www.g2gconsulting.com/event/non-dilutive-funding-g2gs-monthly-gbg-reporting-service-webinar-14-3/2025-09-18/ Key opportunities this month include DARPA’s Expedited Research Innovation System for CBRN threat defense technologies, BARDA’s I-CREATE diagnostic funding and VANGUARD biomanufacturing tools development (each offering up to $200,000), NIAID tuberculosis and influenza research units (up to $1.5–$2.5 million annually), DoD’s $4 million Advanced Medical Monitor development through MTEC, and multiple SBIR opportunities for sensors and field-deployable diagnostics (up to $209,575 for Phase I awards). The September GBG report highlights 13 immunology and infectious disease opportunities, 10 cognitive and brain health programs, and several biotechnology and biomanufacturing initiatives across federal agencies including the Army, ARPA-H, BARDA, and NSF. Georgia Life Sciences members can access the complete 29-page report with detailed deadlines and eligibility requirements [insert link or portal instructions here]. GLS members can access the full 29-page report with deadlines and submission details by logging into your member portal.
By Maria Thacker Goethe September 5, 2025
Protecting U.S. Leadership in Agricultural Biotechnology
By Maria Thacker Goethe August 29, 2025
Celebrating the Next Generation of Scientific Breakthroughs in Georgia
MORE POSTS